

Table S1. Stage and clinical course of AKI during chemotherapy (n=36 patients).

(A) Stage of AKI during chemotherapy (n=36)

	AKI stage I	AKI stage II	AKI stage III
Episodes of AKI	33 (91.8 %)	1 (2.7%)	2 (5.5%)

(B) Clinical course of AKI during chemotherapy

AKI during chemotherapy		Clinical course, number of patients (%)			
Cause	Patients (n=36)	Complete recovery from AKI (n=16)	AKI progress to CKD (n=19)	ESRD (n=0)	Death with functioning kidney (n=1)
Platinum	24	8 (33.4)	15(62.5)	0	1 (4.1)
Contrast-induced nephropathy (CIN)	5	4 (80.0)	1 (20.0)	0	0
Volume depletion	4	2 (50.0)	2 (50.0)	0	0
Other toxic AKI	1	0	1 (100.0)	0	0
Septic AKI	1	1 (100.0)	0	0	0
Post-renal AKI	1	1 (100.0)	0	0	0

AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease.

Fig S1. Profile of patients with lung cancer who received first-line palliative chemotherapy.

